from davidhealy.org<\/a><\/p>\n
| <\/p>\n From: Rasi Guido<\/strong> <Guido.Rasi@ema.europa.eu> Date: 5 December 2013 11:10 Subject: Update on EMA appeal of EU Court interim measures decision in AbbVie and InterMune court cases To: <\/p>\n \n \n Dear colleagues and friends,<\/p>\n I have written a number of times over the past months to keep you informed of developments in the AbbVie and Intermune cases.<\/p>\n There is an important news I would like to share with you concerning the appeal procedures lodged by the EMA in Cases C-389\/13 (P) R and C-390\/13 (P) R.<\/p>\n As you recall, early in July this year the EMA lodged appeals against the Orders of the President of the General Court suspending the decisions to disclose under Regulation (EC) No 1049\/2001 documents contained in the dossier for marketing authorisation of the medicinal products Humira and Esbriet.<\/p>\n We have been recently notified of the two Orders of the Vice-President of the Court of Justice annulling the previous Orders and referring back the cases to the General Court for a new decision on the interim relief applications. The ordinary procedures will follow their normal course.<\/p>\n In the Orders, the Vice-President of the Court of Justice concludes that the President of the General Court erred in law in finding that the alleged infringement of the companies’ fundamental right to the protection of their business secrets and of their right to an effective remedy was sufficient in itself to establish the risk of serious and irreparable harm in the circumstances of the present cases.<\/p>\n Accordingly, the Vice-President of the Court of Justice asks the President of the General Court to examine one by one, the arguments and evidence put forward by the companies and intended to prove the serious and irreparable harm to those companies. In the event that the companies produce such proof with regard to certain information or certain documents, the Vice-President of the Court of Justice explicitly provides that the interim measure sought be granted to them, in respect of that information or those documents only.<\/font><\/strong><\/p>\n The full text of the Orders will shortly be available on the website of the Court of Justice www.curia.europa.eu<\/a> [see this<\/font><\/a>].<\/p>\n Although we have not won the case yet, this is a first important result since the litigation started. We would like to share with you our positive feelings and would like to thank you again for your continuing support, contribution and inspiration for the achievement of our common transparency objectives.<\/p>\n Kind regards<\/p>\n Guido<\/p>\n Guido Rasi<\/strong><\/p>\n Executive Director <\/font><\/td>\n<\/tr>\n<\/table>\n While shrouded in legalese, this case is central in the march towards data transparency because it pits the business interests of the pharmaceutical industry directly against the health interests of the patient\/consumer. Very important case, this one… <\/p>\n Over 6000 of you from more than 120 countries responded.<\/em><\/p>\n |